Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy
- PMID: 21095071
- DOI: 10.1016/j.ijrobp.2010.09.030
Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy
Abstract
Purpose: Chemoradiation for anal cancer yields effective tumor control, but is associated with significant acute toxicity. We report our multi-institutional experience using dose-painted IMRT (DP-IMRT).
Patients and methods: Between August 2005 and May 2009, 43 patients were treated with DP-IMRT and concurrent chemotherapy for biopsy-proven, squamous cell carcinoma of the anal canal at two academic medical centers. DP-IMRT was prescribed as follows: T2N0: 42 Gy, 1.5 Gy/fraction (fx) to elective nodal planning target volume (PTV) and 50.4 Gy, 1.8 Gy/fx to anal tumor PTV; T3-4N0-3: 45 Gy, 1.5 Gy/fx to elective nodal PTV, and 54 Gy, 1.8 Gy/fx to the anal tumor and metastatic nodal PTV >3 cm with 50.4 Gy, 1.68 Gy/fx to nodal PTVs ≤ 3 cm in size. Acute and late toxicity was reported by the treating physician. Actuarial analysis was performed using the Kaplan-Meier method.
Results: Median age was 58 years; 67% female; 16% Stage I, 37% II; 42% III; 5% IV. Fourteen patients were immunocompromised: 21% HIV-positive and 12% on chronic immunosuppression. Median follow-up was 24 months (range, 0.6-43.5 months). Sixty percent completed chemoradiation without treatment interruption; median duration of treatment interruption was 2 days (range, 2-24 days). Acute Grade 3+ toxicity included: hematologic 51%, dermatologic 10%, gastrointestinal 7%, and genitourinary 7%. Two-year local control, overall survival, colostomy-free survival, and metastasis-free survival were 95%, 94%, 90%, and 92%, respectively.
Conclusions: Dose-painted IMRT appears effective and well-tolerated as part of a chemoradiation therapy regimen for the treatment of anal canal cancer.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):27-33. doi: 10.1016/j.ijrobp.2012.09.023. Epub 2012 Nov 12. Int J Radiat Oncol Biol Phys. 2013. PMID: 23154075 Free PMC article. Clinical Trial.
-
Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.Cancer Invest. 2015 Jul;33(6):259-66. doi: 10.3109/07357907.2015.1028586. Epub 2015 May 7. Cancer Invest. 2015. PMID: 25950188 Clinical Trial.
-
Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):587-94. doi: 10.1016/j.ijrobp.2014.06.061. Epub 2014 Sep 3. Int J Radiat Oncol Biol Phys. 2014. PMID: 25194664
-
Treatment of the Primary Tumor in Anal Canal Cancers.Surg Oncol Clin N Am. 2017 Jan;26(1):73-90. doi: 10.1016/j.soc.2016.07.003. Surg Oncol Clin N Am. 2017. PMID: 27889038 Review.
-
Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer.Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1455-62. doi: 10.1016/j.ijrobp.2011.12.058. Epub 2012 Mar 6. Int J Radiat Oncol Biol Phys. 2012. PMID: 22401917
Cited by
-
Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.Acta Oncol. 2016;55(2):208-16. doi: 10.3109/0284186X.2015.1043396. Epub 2015 May 18. Acta Oncol. 2016. PMID: 25984929 Free PMC article. Clinical Trial.
-
Correcting rotational error in rectal cancer radiation therapy: Can planning target volume margins be safely reduced?J Med Radiat Sci. 2022 Dec;69(4):473-483. doi: 10.1002/jmrs.602. Epub 2022 Jun 18. J Med Radiat Sci. 2022. PMID: 35715996 Free PMC article.
-
Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2018 Jul;16(7):852-871. doi: 10.6004/jnccn.2018.0060. J Natl Compr Canc Netw. 2018. PMID: 30006428 Free PMC article.
-
The rising challenge of non-AIDS-defining cancers in HIV-infected patients.Clin Infect Dis. 2012 Nov;55(9):1228-35. doi: 10.1093/cid/cis613. Epub 2012 Jul 9. Clin Infect Dis. 2012. PMID: 22776851 Free PMC article. Review.
-
Improved treatment outcome and lower skin toxicity with intensity-modulated radiotherapy vs. 3D conventional radiotherapy in anal cancer.Strahlenther Onkol. 2020 Apr;196(4):356-367. doi: 10.1007/s00066-019-01534-6. Epub 2020 Jan 24. Strahlenther Onkol. 2020. PMID: 31980834 English.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical